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The global impact of sexually transmitted infections (STIs) is significant. The sexual transmission of viruses such as herpes simplex
virus type-2 (HSV-2) and the human immunodeficiency virus type-1 (HIV-1), has been especially difficult to control. To date,
no effective vaccines have been developed to prevent the transmission of these STIs. Although antiretroviral drugs have been
remarkably successful in treating the symptoms associated with these viral infections, the feasibility of their widespread use for
prevention purposes may be more limited. Microbicides might provide an attractive alternative option to reduce their spread.
In particular, topically applied small inhibitory RNAs (siRNAs) have been shown to not only block transmission of viral STIs to
mucosal tissues both in vitro and in vivo, but also confer durable knockdown of target gene expression, thereby circumventing the
need to apply a microbicide around the time of sexual encounter, when compliance is mostly difficult. Despite numerous clinical
trials currently testing the efficacy of siRNA-based therapeutics, they have yet to be approved for use in the treatment of viral STIs.
While several obstaclestotheirsuccessful implementation intheclinic stillexist,promisingpreclinical studiessuggest thatsiRNAs
are a viable modality for the future prevention and treatment of HSV and HIV.
1. Clinical Context
Sexually transmittedinfections(STIs) continueto be a major
source of global morbidity and mortality[1]. Viralinfections,
notably herpes simplex virus type-2 (HSV-2) and the human
immunodeficiency virus type-1 (HIV-1), have proven partic-
ularly problematic to control from both scientific and public
health perspectives.
HSV-2, the most common cause of genital ulcers, is the
most widespread viral sexually transmitted infection (STI)
worldwide [2]. Prevalence is high; currently estimated to be
∼15–25%ofsexuallyactiveadultsintheUSandashighas60–
80% in some developing nations [2–5]. Rates of infection are
even higher among women, owing to the greater efficiency
of male-to-female (MTF) transmission [6, 7]. While multiple
variablesfactorintothehighprevalencerateatthepopulation
l e v e l ,t h ef a c tt h a tm o s ts e x u a lt r a n s m i s s i o n so c c u ri nt h e
absence of clinically identifiable genital lesions likely plays
am a j o rr o l e[ 8, 9]. While antiviral drugs have proven
effective to reduce viral transmission [6, 8, 10], they are not
curative. Furthermore, due to the high costs associated with
population-wide screening and maintenance therapy, their
utility as public health initiatives to reduce transmission is
debatable [11] .Th i si se s p e c i a l l yt r u ew h e nm o r ee c o n o m i c a l
interventions, such as condoms, are known to be similarly
effective for prevention purposes [12, 13]. Nonetheless, the
numbers of infected individuals continues to rise under-
scoring the need for developing new modalities to reduce
transmissionandclearwhatarecurrentlylife-longinfections.
Epidemiological analysis has established a link between
t h ep r e v a l e n c eo fH S V - 2a n dH I V - 1[ 3]. In fact, individuals
i n f e c t e dw i t hH S Va r ea tg r e a t e rr i s ko fa c q u i r i n gH I Va ft e r
exposure, underscoring the fact that herpes infection is an
important cofactor for HIV transmission [4, 14–16]. While
the prevalence of HIV-1 is much lower than that of HSV-
2, the global burden of HIV is significant. An estimated 60
million people have been infected by the virus, and some 30
million people are currently living with HIV [17]. Research
onHIVvaccinedevelopmentbeganalmostimmediatelyafter
HIV was identified as the causative agent for AIDS [18–21].
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However,todate,noeffectivevaccinesagainstHIVhavebeen
developed [22–24]. Since 1996, there has been a dramatic
decline in the clinical burden associated with HIV infection
with the introduction of highly active antiretroviral therapy
(HAART), an approach predicated on the simultaneous
pharmacological inhibition of multiple components of the
virallifecycle[25,26].HAARThassignificantlyreducedboth
themortalityandmorbidityassociatedwithHIVanditisnow
thestandardofcareforthetreatmentofHIVinbothchildren
and adults [27–30]. Continued challenges to HIV control
includedrugresistance,poorcompliance,andlimitedaccess,
especially in the developing world [31–43]. Importantly, due
to the persistence of viral reservoirs in infected individuals,
HAART cannot eliminate virus from the seroconverted host
[44–48].
Therefore, a combination of therapeutic and preventative
approaches is needed to effectively manage the growing
epidemic [49]. While preexposure prophylaxis (PrEP) has
proven an effective approach to preventing transmission [50,
51],highcost,potentialsideeffects,andpossibledevelopment
of drug resistance suggest that PrEP may be best suited to
targeteduseinonlythehighest-riskpopulations[52,53].That
being said, given that 2.7 million people were newly infected
with HIV in 2010 alone [54], the continued spread of the
infection underscores the urgent need for the development
of novel ways to prevent viral transmission.
An extensive body of knowledge and research that has
accumulated over the past decades on viral transmission and
pathogenesis, however HSV-2 and HIV-1 continue to present
formidable scientific and public health challenges. Vaccines
a r eo ft e nc o n s i d e r e dt h eg o l ds t a n d a r df o rp r e v e n t i o no fv i r a l
infection;buthistorically,vaccinestrategiesagainstviralSTIs
have proven ineffective [55–61]. While more recent vaccine
candidates against HIV-1 and HSV-2 have shown a modest
protective effect, none have yet been FDA approved for use.
Infact,thevaccineagainstthehumanpapillomavirus(HPV)
is the only vaccine currently available and approved for the
prevention of a viral STI [62–65]. While its cost is still
prohibitiveinmostdevelopingcountries,ithasprovenhighly
effective against the primary strains of HPV known to cause
both genital warts and cervical cancer. In the absence of an
effectivevaccineagainstHSV-2andHIV-1,theglobalburden
o fd i s e a s e ,c o s to ft r e a t m e n t ,a n dl a c ko fc u r ea l ls e r v et o
highlight the need for research into alternative interventions
to prevent the transmission of viral STIs.
2. STI Microbicides
One particularly attractive option is a topical microbicide,
which could reduce sexual transmission of the virus at the
mucosal site of entry [66, 67]. Several microbicidal com-
pounds targeting HIV-1, HSV-2, and HPV are being assessed
in clinical trials, and more are currently under investigation
[68].
Theearliestmicrobicidecandidatesweresurfactants,such
as nonoxynol-9 (N9), that showed antiretroviral activity
against both HIV and HSV in vitro by disrupting the mem-
b r a n ec o a to ft h ev i r u s[ 69–71]. When applied intravaginally,
however, N9 led to higher rates of HIV infection [72–75].
Becausethiswasmostlikelysecondarytotheinflammationit
induces in the genital tract, further studies against both HIV
and HSV were subsequently abandoned.
Over the past two decades of research in the field,
multiple alternative vaginal microbicide strategies—ranging
from acid buffering gels [76] to polyanionic inhibitors of
virus entry [77]—have been tested both in vitro [78]a n d
clinically [79] with little success. Most rectal formulations
have been based on those models successful in preclinical
trials for vaginal application and have met with a similar fate.
To date, only one has demonstrated clinical efficacy, both
againstHIVandHSV-2[80]:avaginallyapplied1%tenofovir
gel, which was the first microbicide tested clinically that
afforded study participants protection from viral transmis-
sion. While protection was only partial, CAPRISA004 served
as the catalyst for further study on topical tenofovir gels,
including those intended for rectal administration [81, 82].
While follow-up studies have failed to reproduce the partial
protection observed in CAPRISA004 [83], post hoc data
analysis suggests that this was due in large part to inadequate
compliance of study subjects to the treatment regimen.
The future of tenofovir gel as a preventative microbicide
remains unclear, but this first success story in the decade-
long history of research in microbicide development has gal-
vanized interest in working toward designing a viable topical
microbicide to prevent the sexual transmission of HSV and
HIV.
3. The RNAi Revolution
RNA interference (RNAi) is a cost-effective means of sup-
pressing the expression of virtually any gene in a sequence
specific manner [84, 85]. The field began early in the 1990s,
with the discovery that small RNA molecules had the
a b i l i t yt or e g u l a t ed e v e l o p m e n t a lt i m i n gi nt h en e m a t o d e
Caenorhabditis elegans and trans gene expression in plants
[86–88]. Nonetheless, it was the seminal discovery by Fire
and colleagues in 1998 that conclusively demonstrated how
these RNAs could be used to modulate gene expression [85].
The term RNA interference, or RNAi, came to refer to the
processofintroducingsmalldsRNA,termedsmallinhibitory
RNAs (siRNAs), to silence gene expression in a sequence
specific manner. When it was later demonstrated to function
similarly in mammalian cells, we came to understand it
as well-conserved endogenous gene regulatory mechanism
that could be harnessed as an experimental tool for the
analysis of gene function. In so doing, it also opened the
door for the development of novel therapeutic approaches
for multiple diseases, including viral pathogens (e.g., HIV-1
[89–93], respiratory syncytial virus [RSV] [94], and herpes
simplex virus-2 [95, 96]), inflammatory disorders [97–100],
and a variety of cancers [101, 102].
Therapeutically relevant siRNAs can be introduced to
the endogenous RNAi pathway at various stages (Figure 1).
For example, siRNAs can be derived from short hairpin
sequences (shRNAs) introduced to the host genome by
viral vectors [103], which follow much the same processingInfectious Diseases in Obstetrics and Gynecology 3
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Figure 1: Cellular machinery for RNAi-mediated gene silencing. (a) miRNA-mediated gene silencing. miRNAs (endogenous) and shRNAs
(exogenous—lentiviral vectors) are expressed from Pol II-derived primary transcripts (pri-miRNA/pri-shRNA). The pri-miRNA/shRNA is
cleaved by Drosha, an RNase III-type enzyme, producing the precursor miRNA/shRNA (pre-miRNA/shRNA), which is exported into the
cytoplasmbyexportin-5.Onceinthecytoplasm,theloopofthepre-miRNAiscleavedoffbyDicer,producingthetransientlydouble-stranded
miRNA, which is taken up by the miRNA-containing RISC (miRISC). The passenger strand rapidly dissociates, leaving the single-stranded
mature miRNA to guide the sequence-specific inhibition of translation or cleavage of the target mRNA. shRNA is processed in a similar way
but has been introduced to the host genome exogenously, often by lentiviral vector. (b) siRNAs, 19–21 nucleotide duplexes, are processed by
Dicer to generate 2-3 nucleotide overhangs at their 3
򸀠 ends and phosphate groups on their 5
򸀠 termini., thereby activating the siRNAs. Active
siRNAs are then incorporated into the RISC. The passenger strand of the duplexed siRNA is cleaved and released from the complex, leaving
the single-stranded guide strand to direct RISC to the complimentary site on the target mRNA. Ago2 catalyzes the cleavage of target mRNA
in trans, and the cleaved mRNA is released and the active strand containing RISC can direct the cleavage of additional target mRNAs. Ago:
argonaute; RISC: RNA-induced silencing complex. Figure is adapted from [105].
pathways as endogenous microRNAs (miRNAs). After tran-
scription,shRNAsarecleavedinthenucleusbytheRNAseIII
Drosha,afterwhichtimetheyareexportedintothecytoplasm
via exportin-5, and processed by Dicer into siRNAs [104].
Synthetic siRNAs, introduced exogenously to the cytoplasm,
bypass much of the host RNAi machinery, converging at the
point of Dicer-mediated processing [84].
Both siRNAs and miRNAs that are produced by Dicer
act as effector molecules that, through their association
with the RNA-induced silencing complex (RISC), guide the
sequence-specific inhibition of gene expression. The critical
component of RISC is an argonaute (Ago) protein that
not only provides the siRNA/miRNA binding site, but also
contains the endonucleolytic domain that cleaves comple-
mentary mRNA targets.
While, structurally, the siRNA/miRNA strands are sym-
metric,functionally,theyarenotequivalent[106].Thestrand
exhibiting the lower thermodynamic stability upon biding
to RISC predominates as the active (antisense) strand used
to guide the silencing of target mRNA expression, while the
inactive (sense) strand is either cleaved or released from
the complex [107]. Strand bias is a critical feature in siRNA
design, since it determines target specificity. Most perfectly
complimentary sequences (like most siRNAs) allow for site-
specific cleavage of the target mRNAs by argonaute 2, an
RNAse III enzyme, at predictable and verifiable locations,4 Infectious Diseases in Obstetrics and Gynecology
namely, distal to the 10th nucleotide from the 5
򸀠-end of the
guidestrand[104,108].CleavedtargetmRNAissubsequently
released from the complex and degraded, allowing for the
activated RISC to effect subsequent rounds of cleavage.
Originally, imperfectly complimentary sequences (like some
miRNAs) were thought to only block downstream transla-
tion of mRNA strands [109]. Recent evidence suggests that
some target cleavage does indeed occur [110, 111], however
more robust target gene silencing is observed with perfectly
homologous sequences and, thus, will be the focus of this
review.
4. Antiviral Activity of RNAi
Soon after RNAi was shown to operate in mammalian cells,
severalgroupsdemonstratedthatsmallinhibitoryRNAs(siR-
NAs)couldbeusedtointerferewithbothofthetransmission
and replication of HIV-1, HSV-2, and HPV in vitro and in
vivo [112, 113]. For HIV infection, siRNAs can inhibit viral
replication in vitro by either directly targeting sequences of
viral gene products [105, 114–117] or silencing essential host
factors (EHFs) [118], such as the HIV receptor CD4 [89]o r
the CCR5 coreceptor [92] required for productive infection
(Figure 2). For antiviral siRNAs, targeting a single conserved
HIV-1 sequence is able to inhibit primary isolates from all
viralclades[90].Accordingly,ajudiciousselectionofsiRNAs
directed against highly conserved viral gene products might
allow for the simultaneous inhibition of diverse strains of
HIV present throughout the world. Similar approaches have
been validated for HSV-2 infection, where siRNAs directed
against the nectin-1 cell surface receptor required for viral
entry, and viral gene products UL27/UL29 essential to the
viral life cycle, effectively inhibit replication. Importantly, the
inhibitory effect is more pronounced when targeting both
h o s ta n dp a t h o g e ng e n ep r o d u c t s ,s u g g e s t i n gt h a ts y n e r g i s t i c
effects could play an important role.
Early approaches focused primarily on systemic delivery.
While this delivery method has potential utility for postin-
fection therapeutics, systemic administration is unlikely to
p r e v e n ti n f e c t i o na tt h es i t eo fe n t r y .Th ep r o o fo fp r i n c i p l e
that topically-applied siRNAs are taken up and effect gene
silencing at the mucosa was first shown using a model of
respiratorysyncytialvirus(RSV)infection[94,120,121],con-
firming that siRNA-mediated protection from viral infection
is in fact possible in mucosal tissues.
Establishing stable viral resistance in the genital tract to
prevent sexual transmission of viruses may be possible based
on recent studies of other sexually transmitted infections
(STIs).Usingamousemodelofherpesinfection,intravaginal
(IVAG) application of siRNAs targeting HSV-2-encoded
genes and/or its cellular receptor, nectin-1, inhibited sexual
transmission of HSV-2 for more than one week [95, 96].
Similarly,siRNAsagainsttheCCR5coreceptorandviralgene
products gag and vif have demonstrated protection from
vaginal infection in a newly developed small animal model
for HIV infection [122, 123].
To address the considerable problem of patient com-
pliance faced by most microbicidal intervention strategies,
ensuring durable gene silencing is critical, since lasting
knockdown would likely circumvent the need to apply
the microbicide prior to each sexual encounter [124]. Two
approaches to date have proven effective in this regard. Con-
jugation of siRNAs to cholesterol moieties prolonged half-
life in the vaginal mucosa of mice challenged with HSV-2,
maintaining protection even when viral challenge is delayed
[96]. For HIV, similar approaches were not possible since
the immune cells HIV infects are refractory to transfection
with cholesterol conjugated siRNAs. While siRNAs directed
against CCR5 were known to effectively silence target gene
expression in vitro and prevent viral replication in primary
macrophages when challenge is delayed for up to 3 weeks
[89], only recently was testing possible in an in vivo model.
Using CD4 aptamers as targeting vehicles, siRNAs against
C C R 5w e r es h o w nt op r o t e c tf r o mv a g i n a lt r a n s m i s s i o no f
the virus when applied 4-5 days prior to viral challenge, and
inhibition of viral replication was observed when applied
up to one week prior to challenge [122]. While additional
testing will be required to confirm these preliminary studies,
these data suggest that repeated siRNA applications may
have an additive effect. In other words, they may confer
durable protection from STIs such as HIV when applied
every few days, thereby obviating the need for application
just prior to sexual encounters, when compliance is most
difficult.
5. RNAi Therapeutics:
The Challenge of Delivery
Despite the potential promise of antiviral siRNAs for therapy
or prevention, the primary obstacle to their widespread clin-
ical application has been delivery; more specifically, finding
an efficient means of shuttling exogenous siRNAs across the
plasma membrane [112]. Over the years, several techniques
have been employed to successfully deliver siRNAs to cells
for gene knockdown, including cationic lipids, lentiviral
vectors, and conjugation to other molecules such as PEG
or cholesterol [125–132]. While these approaches successfully
overcome the first barrier to effective siRNA delivery, that is,
the plasma membrane, they typically fail to target siRNAs to
the cells of interest; that is, they lack cell specificity.
Targeted siRNA delivery may not be essential for all
potential clinical applications. Nonetheless, targeting siRNA
therapeutics to a specific subset of cells or tissue types may
have some significant advantages relative to non-specific
administration.Inparticular,itwouldminimizenon-specific
effects and toxicity in bystander cells; and, perhaps more
importantly,itwouldreducethedoserequiredfortherapeutic
silencing in the cells and tissues of relevance. For viral
S T I s ,t a r g e t e dd e l i v e r yh a sn o tb e e nn e c e s s a r yf o ri n h i b i t i n g
HSV-2. When applied topically to the genital mucosa, the
epithelial cells HSV-2 infects readily endocytose both naked
and cholesterol conjugated siRNAs, which effect target gene
silencing after uptake. HIV has been proven more difficult
to prevent in a similar way, primarily because the CD4+
immune cells HIV infects are particularly refractory to most
traditional methods of transfection [89, 92]. As a result,Infectious Diseases in Obstetrics and Gynecology 5
Figure 2: siRNAs directed against either conserved HIV-1 sequences or essential host factors (EHFs) could impair HIV-1 replication at
various points in the viral life cycle.Although the incoming viral RNA is protected from siRNA-mediated degradation by its association with
the preintegration complex (PIC) [119], it is possible to interfere with EHFs required for viral entry or integration by targeting its receptor
CD4,itscoreceptor,orfactorsrequiredforentryintothenucleussuchastransportin-3.TargetingconservedHIV-1sequencescanalsoinhibit
progeny virus formation by cleaving HIV-1 transcripts such as gag and pol, expressed by the integrated proviral DNA. Figure is adapted from
[105].
siRNA-based interventions have had to overcome the obsta-
cle of in vivo transduction of CD4+ cells.
Targeted delivery has become possible in recent years
using bifunctional fusion proteins, which couple a targeting
antibody fragment (Ab) to an RNA binding motif, such as
protamine. Using Fabs recognizing cell surface receptors,
such as the lymphocyte function-associated antigen (LFA-1)
[98] or the HIV glycoprotein gp120 [93], functional siR-
NAs have been effectively delivered to relevant cell types,
even in vivo [91]. Despite these promising results, critics of
the antibody-based approach cite difficulties with synthesis,
high manufacturing and storage costs, chemical instability,
and potential immunogenicity as important limitations for
widespread use. Given that HIV-1 and HSV-2 are most
prevalent in the developing world and given the economic
and storage requirements, they may not be ideally suited for
use as preventative microbicides, especially in resource poor
settings.
More recently, small structured oligonucleotides, called
aptamers, provide a promising alternative option for siRNA
delivery. Aptamers can be efficiently and economically syn-
thesized in large scale, and they are amenable to mul-
tiple chemical modifications. Moreover, because they are
rarely immunogenic, aptamers are ideally suited for ther-
apeutic applications like topical microbicides, which may
require repeated administration. Synthesized from random-
ized oligonucleotide libraries, aptamers are in vitro selected
for their ability to bind a desired ligand with high affinity.
Th e yh a v eb e e nu s e di ns e v e r a ld i s e a s em o d e l s[ 133], includ-
ing HIV, primarily for their receptor-blocking properties
[134, 135].
Aptamers were recently demonstrated as potential deliv-
ery vehicles for siRNA. Using a ligand-targeting aptamer
fused at its 3
򸀠-end to an siRNA duplex, these aptamer-siRNA
chimeras (AsiCs) were first used to transfect and silence
gene expression in prostate cancer cells both in vitro [136]
and in vivo [137] using a prostate-membrane specific antigen
(PSMA) aptamer. AsiCs, constructed using a gp120-targeting
aptamer, were tested in vitro and, more recently, in vivo
[138–140] and reduced viral replication in infected hosts.
A second strategy using CD4-targeting aptamers has also
demonstrated effectiveness by both inhibiting HIV replica-
tion and blocking transmission of the virus in vivo [122,
123] .M e r g i n gb o t ha p p r o a c h e sw o u l dl i k e l yb ee v e nm o r e
effective, by coupling a method to prevent de novo infection
in CD4+ cells susceptible to HIV infection with another that
effectively inhibits viral replication in the small number of
cells that may become infected with HIV, the virus after
e x p o s u r e .C o m b i n a t o r i a la p p r o a c h e s ,k n o w nt ob eh i g h l y
effective against viruses such as HIV given past experience
with HAART, capitalize on the aptamer’s ability to block
HIV entry at CD4, as well as specifically to deliver siRNAs
that inhibit factors required for both viral transmission and
replication.6 Infectious Diseases in Obstetrics and Gynecology
6. Future Prospects
From its first discovery, less than 20 years ago, the field of
RNAinterferencehasevolvedatarapidpace.Thepotentialto
silencetheexpressionofvirtuallyanygeneproducthasfound
applications outside of the lab and has now been successfully
applied to the treatment and prevention of several diseases,
including viral STIs. Despite these successes, a number of
challengesremainfortheeffectiveapplicationofRNAi-based
approaches in the fight against HIV and HSV. The brisk
development of technological innovations in the field has in
many ways outpaced our understanding of basic biology of
RNAi. As we better understand the underlying biochemical
pathways, we can improve the design, the effectiveness,
and the side effect profile of these reagents to maximize
their therapeutic index. Furthermore, for both therapeutic
and preventative purposes, multiple applications over long
periods of time may be required. While largely dependent
on patient-specific factors such as burden of disease and risk
of exposure, this underscores the need for further studies
investigatingtheeffectsofrepetitiveadministrationandlong-
term use.
The most well-developed therapeutic approaches using
siRNAhaveusedlocalizeddeliverytoeasilyaccessibleorgans
and tissues, including treatment of the eye for age-related
macular degeneration or the treatment of lungs for RSV
infection [105]. While HSV-2 appears to be effectively con-
trolled with similar tissue-based applications, HIV-1 poses
a more difficult challenge. Because it infects multiple cell
types that are spread throughout the body, utilizing new
modalities (antibodies, aptamers, etc.) to deliver functionally
active siRNAs to specific CD4+ target cells will likely be
required for future siRNA-based approaches to be effective.
Irrespective of the specific delivery mechanism used, the
combination of multiple siRNAs targeting either multiple
conservedsitesontheHIV-1genomeorviralandhostfactors
will undoubtedly minimize the potential for viral escape
mutations and, thus, be the most effective strategy. While
targeting new host factors implicated in disease pathogenesis
could prove useful to identifying new ways to prevent viral
transmission, care must be taken in selecting such targets to
minimize off-target effects.
While the mouse model has been indispensible for
studying topical siRNA-based interventions for both HSV-
2[ 95, 96]a n dH I V - 1[ 122, 123, 141, 142], translating these
results into safe and cost-effective therapies for clinical use in
humans remains a significant challenge. Nonhuman primate
(NHP) models have traditionally been used to bridge the gap
between small animal models and clinical trials, especially
in STI research; however, meaningful differences between
NHP and patient populations do exist. In particular, off-
target effects can manifest themselves in vastly different ways
from one species to the next and can, during preliminary
clinical trials, derail what had been a very promising drug
candidate in preclinical studies. Safety concerns are not
l i m i t e dt oa n i m a lm o d e l s ,h o w e v e r ,a st h er e c e n tt e r m i n a t i o n
of the phase III trial targeting macular degeneration using
VEGF-specific siRNAs has highlighted [143]. Along with
other studies, this has underscored potential bias introduced
by nonspecific effects and reinforced the need to rigorously
demonstrate siRNA-mediated mechanisms of action at every
stageofdevelopment.InthecaseofRNAi-basedtherapeutics,
this becomes especially important when specific chemical
modifications have been made or new moieties have been
conjugated to siRNA strands for targeting, stability, or other
purposes [131, 144, 145].
Given that RNAi-based therapeutics are predicated on
the introduction of exogenous RNA to the cytoplasm, it is
perhaps not surprising that some reports have found that
siRNAs can trigger a type I interferon (IFN) response. Trig-
gering toll-like receptors that recognize intracellular nucleic
acids activates a nonspecific immune response that generally
blunts knockdown of target genes and produces unwanted
sideeffects[146–148].While,incertaincircumstances,anon-
specific IFN response can enhance the observed therapeutic
effect [149, 150], generally, strategies focus on minimizing
these off-target effects. To date, substitutions such as 2
򸀠-
OMelinkages[151],modifiedDNA/RNAbases[152,153],and
designenhancementstoimprovethechemicalstabilityofthe
siRNA moiety [154]h a v eb e e ne m p l o y e dw i t hs o m es u c c e s s .
Nonetheless,reportsexistinwhichmodificationsofthistype
did not blunt the innate immune response [155], suggesting
that alternative approaches to “mask” siRNAs from TLR
recognition would be required [131, 156].
Overexpression of small RNAs can also be problematic.
Typically associated with lentiviral shRNA constructs, over-
expression can result in saturation of the endogenous RNAi
machinery, perturbations of normal miRNA function [157],
and even fatal brain toxicity in small animal models [158].
WhileusingsiRNAsinsteadofshRNAscancircumventthese
adverse outcomes [159], high concentrations of siRNAs have
similar detrimental effects [157]. This underscores the need
to improve the potency of siRNA-based constructs while
minimizing potential off-target effects. While biochemical
a n ds t r u c t u r a lm o d i fi c a t i o n sh a v eb e e nu s e dt oi m p r o v e
potency with some success [151, 152, 160, 161], combinatorial
approaches to target gene silencing have also proven useful
to reduce the effective concentration of siRNA required for
therapeutic effect. Combinatorial approaches do increase
competition for RISC loading [94, 162]a n dt h u sm a yr e s u l t
in impaired silencing of one or more target genes depending
on factors such as relative chemical stability and affinity for
the RISC.
Given the increasing incidence of worldwide infections
with both HIV-1 and HSV-2, developing new ways to prevent
transmission is essential. Topically applied siRNAs have
b e e ns h o w nt on o to n l yb l o c kt r a n s m i s s i o no ft h ev i r u s
to tissue both in vitro and in vivo but also confer durable
knockdown of target gene expression [95, 96, 122, 123,
163]. Patient compliance will determine the success of any
therapeutic intervention, including a topical microbicide, as
recentclinicaltrialstestingtheefficacyoftenofovir-basedgels
have demonstrated [80, 83]. These findings underscore the
importanceofdevelopinginterventionsanddosingschedules
that are not too burdensome to the user, in order to facilitate
adherence. Agents that confer durable protection might
circumvent the need to apply a microbicide around the
time of sexual encounter, when compliance is most difficultInfectious Diseases in Obstetrics and Gynecology 7
[79, 124].In somecasesthen,RNAi—whichhasalreadybeen
showntoknockdownmultipletargetgenesinvariousdisease
models for several weeks at a time both in vitro and in
vivo [92, 95, 96, 99, 105]—may be an ideal choice. Despite
numerous clinical trials currently underway to evaluate the
efficacyofRNAi-basedtherapeutics[164],theyhaveyettobe
approved for use in the treatment of viral STIs. While several
obstacles to their successful implementation in the clinic still
exist, reassuring data highlights the future promise of RNAi
as a viable modality for the prevention and treatment of HIV
and HSV.
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